Is BioNTech SE (BNTX) A Good Stock To Buy Now?

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ ...
Barron's

BioNTech SE ADR

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

BioNTech SE (BNTX) Rallying on Solid Oncology Strategy

BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from ...

BioNTech: The Market Is Pricing Low Oncology Success

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum Shift

BioNTech share performance snapshot BioNTech (NasdaqGS:BNTX) has seen mixed share price moves recently, with a small 1 day decline, a gain over the past week, a loss over the past month, and a ...
Nasdaq

BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...